Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Impact of Creatinine Clearance in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP : A Real-World Long-Term Observation Analysis at a Single Institute

Noriko Nishimura, MD PhD, Takanori Fukuta, MD, Anna Nishihara, MD, Yuko Shirouchi, MD, Hideki Uryu, MD, Norihito Inoue, MD, Yoshiharu Kusano, MD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 5399.

https://doi.org/10.1182/blood-2018-99-115897

Published: 2018

Journal Articles

Retrospective Analysis of Adults with Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Matthew Tenold, MD BS, Benjamin Moskoff, PharmD, David Benjamin, MD, Brian A. Jonas, MD PhD

Blood (2018) 132 (Supplement 1): 1424.

https://doi.org/10.1182/blood-2018-99-119593

Published: 2018

Journal Articles

Lenalidomide and Dexamethasone Therapy in Elderly Patients with Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide

Takahiro Kobayashi, MD, Masatomo Miura, Takenori Niioka, Yuki Fujioka, Maiko Abumiya, Tomoko Yoshioka, Yoshihiro Kameoka, Hiroyoshi Nishikawa, Naoto Takahashi

Blood (2017) 130 (Supplement 1): 3846.

https://doi.org/10.1182/blood.V130.Suppl_1.3846.3846

Published: 2017

Journal Articles

Evaluation of Risk Factors and Survival Effect of Delayed Excretion of High-Dose Methotrexate in Patients with Leukemia and Lymphoma

Kentaro Narita, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2017) 130 (Supplement 1): 4132.

https://doi.org/10.1182/blood.V130.Suppl_1.4132.4132

Published: 2017

Journal Articles

A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit

Guillermo Garcia Manero, Ehab Atallah, MD, Samer K Khaled, MD, Martha Arellano, MD, Mrinal M Patnaik, MBBS, Olatoyosi Odenike, MD, Hamid Sayar, MD, Mohan Tummala, Prapti A. Patel, MD, Richard G. Ghalie, MD, Bruno C. Medeiros, MD

Blood (2016) 128 (22): 100.

https://doi.org/10.1182/blood.V128.22.100.100

Published: 2016

Journal Articles

Successful Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Mild Renal Dysfunction Calculated By Creatinin Clearance

Shuntaro Ikegawa, MD, Tomoko Inomata, MD, Naoto Ikeda, MD, Hiroyuki Sugiura, MD, Taiga Kuroi, MD, Takeru Asano, MD, Shohei Yoshida, MD, Hisakazu Nishimori, MD PhD, Ken-ichi Matsuoka, MD PhD, Nobuharu Fujii, MD PhD, Eisei Kondo, MD PhD, Yoshinobu Maeda, MD PhD, Mitsune Tanimoto, MD PhD

Blood (2016) 128 (22): 4656.

https://doi.org/10.1182/blood.V128.22.4656.4656

Published: 2016

Journal Articles

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Benjamin Lanza, Giovanni Martinelli, Karen W.L. Yee, MD, Lori Jukofsky, Bernhard Reis, PhD, Steven Blotner, PhD, Mark W. Drummond, PhDMD, Norbert Vey, MD PhD, Karen Seiter, MD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Kevin R. Kelly, MD PhD, Margaret Kasner, MD, Michel Theron, PhD, Jeffrey M. Venstrom, Steven Middleton, PhD, Lin-Chi Chen, MD PhD, Nelson Kinnersley, Gwen Nichols, MD, William E. Pierceall, PhD

Blood (2016) 128 (22): 2843.

https://doi.org/10.1182/blood.V128.22.2843.2843

Published: 2016

Journal Articles

Cytogenetic Response Based On Revised IPSS Cytogenetic Risk Stratification and Minimal Residual Disease Monitoringby FISH In MDS Patients Treated By Low-Dose Decitabine

Xiao Li, MD, PhD, Chunkang Chang, Qi He, Feng Xu, Qingxia Zhang, Lingyun Wu, Jiying Su, Xi Zhang, Liyu Zhou, Dong Wu, Zheng Zhang

Blood (2013) 122 (21): 1575.

https://doi.org/10.1182/blood.V122.21.1575.1575

Published: 2013

Journal Articles

The Biocompatibility and Security of Magnetic Nanoparticles Fe 3 O 4 -DNR Used In Hematologic Malignancies Therapy

Bao-An Chen, MD, PhD, Wei-wei Wu, Jian Cheng, Jun Wang, Feng Gao, Wen-lin Xu, Chong Gao, Jia-hua Ding, Yun-yu Sun, Hui-hui Song, Wen Bao, Li-jie Liu, Guo-hua Xia, Xue-mei Wang

Blood (2010) 116 (21): 3970.

https://doi.org/10.1182/blood.V116.21.3970.3970

Published: 2010

Journal Articles

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

Jason C. Chandler, MD, Rebecca B. Klisovic, MD, Mitch A. Phelps, PhD, Alison Walker, MD, Ramiro Garzon, MD, Xiaoxia Yang, Larry Schaaf, PhD, Sebastian Schwind, MD, Heiko Becker, MD, Shujun Liu, PhD, Chris Hickey, Cheryl Kefauver, RN, Jon Mickle, CNP, Steven M Devine, MD, Michael R. Grever, MD, John C. Byrd, MD, Guido Marcucci, MD, William Blum, MD

Blood (2009) 114 (22): 841.

https://doi.org/10.1182/blood.V114.22.841.841

Published: 2009

Journal Articles

WT1 Transcripts Is a Powerful Leukemia Marker to Predict Early Relapse After Allogeneic Haematopoietic Stem Cell Transplantation.

Blood (2009) 114 (22): 4488.

https://doi.org/10.1182/blood.V114.22.4488.4488

Published: 2009

Journal Articles

Romidepsin (Depsipeptide, FK228) Induces Clinically Significant Responses in Treatment-Refractory CTCL: Interim Report of a Phase II Multicenter Study.

Adam Lerner, M.F. Demierre, S. Whittaker, T. Robak, E. Baran, W. McCulloch, A.G. Prentice

Blood (2006) 108 (11): 2468.

https://doi.org/10.1182/blood.V108.11.2468.2468

Published: 2006

Journal Articles

WT1-Peptide Vaccination Shows High Immunogenicity and Clinical Activity in Patients with Acute Myeloid Leukemia.

Keilholz Ulrich, MD, Carmen Scheibenbogen, MD, Anne Letsch, MD, Anne Marie Asemissen, MD, Wolf Karsten Hofmann, MD, Lutz Uharek, MD, Blau Wolfgang, MD, Thiel Eckhard, MD

Blood (2005) 106 (11): 406.

https://doi.org/10.1182/blood.V106.11.406.406

Published: 2005

Journal Articles

Treatment Outcome of Aggressive Lymphoma with CyclOBEAP (CHOP-Like + Etoposide and Bleomycin): Results of Multicenter Trial.

Masataka Okamoto, M.D., Nozomi Niitsu, M.D., Sadao Aoki, M.D., Yasunobu Kuraishi, M.D., Hirokazu Okumura, M.D., Masami Hirano, M.D.

Blood (2004) 104 (11): 3303.

https://doi.org/10.1182/blood.V104.11.3303.3303

Published: 2004

NARROW

Impact of Creatinine Clearance in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP : A Real-World Long-Term Observation Analysis at a Single Institute

Retrospective Analysis of Adults with Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Lenalidomide and Dexamethasone Therapy in Elderly Patients with Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide

Evaluation of Risk Factors and Survival Effect of Delayed Excretion of High-Dose Methotrexate in Patients with Leukemia and Lymphoma

A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit

Successful Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Mild Renal Dysfunction Calculated By Creatinin Clearance

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Cytogenetic Response Based On Revised IPSS Cytogenetic Risk Stratification and Minimal Residual Disease Monitoringby FISH In MDS Patients Treated By Low-Dose Decitabine

The Biocompatibility and Security of Magnetic Nanoparticles Fe 3 O 4 -DNR Used In Hematologic Malignancies Therapy

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

WT1 Transcripts Is a Powerful Leukemia Marker to Predict Early Relapse After Allogeneic Haematopoietic Stem Cell Transplantation.

Romidepsin (Depsipeptide, FK228) Induces Clinically Significant Responses in Treatment-Refractory CTCL: Interim Report of a Phase II Multicenter Study.

WT1-Peptide Vaccination Shows High Immunogenicity and Clinical Activity in Patients with Acute Myeloid Leukemia.

Treatment Outcome of Aggressive Lymphoma with CyclOBEAP (CHOP-Like + Etoposide and Bleomycin): Results of Multicenter Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only